Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has signed three deals that will expand the availability of its pharmacogenomics tests in Asia.

Under the first deal, Admera will gain access to the existing physician network of Angsana Molecular & Diagnostics Laboratory, a molecular diagnostic assay developer with offices in Singapore, Hong Kong, and Malaysia. Under the other two deals, South Korea-based Biois and Taiwan-based AllBio Pharma will distribute Admera's full product portfolio.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.